Compare EBS & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBS | SGHT |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.8M | 309.6M |
| IPO Year | 2006 | 2021 |
| Metric | EBS | SGHT |
|---|---|---|
| Price | $6.67 | $8.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $12.00 | $9.08 |
| AVG Volume (30 Days) | ★ 1.1M | 141.9K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.83 | 28.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $742,900,000.00 | $77,363,000.00 |
| Revenue This Year | $1.29 | $11.67 |
| Revenue Next Year | N/A | $10.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.36 | $3.19 |
| 52 Week High | $14.06 | $9.24 |
| Indicator | EBS | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 64.65 |
| Support Level | N/A | $7.85 |
| Resistance Level | N/A | $8.82 |
| Average True Range (ATR) | 0.00 | 0.31 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 86.17 |
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.